Fair questions for any thread. At this point, I will not address every single competitor, but over time, perhaps you may gain confidence in my breadth.
Our most staunch competition comes from SUGN, since they are "as advanced" as we are.
I will try to address your question better at a time this weekend. In the meantime, I wanted to pass along the citations for the important aspects of what ENMD has. Later, when I respond more thoroughly, I will also give the abstract of the two citations. For now, I would say that few, if any, have demonstrated such striking results, which places a heavy emphasis on ENMD, automatically, over any and all competition. This will offer higher multiples and valuations for the future potential that is here. It also thrusts ENMD onto the front page news, which, to the chagrin of other hard working individuals, emhasizes what ENMD is doing and forgets or excludes everyone else who is busting his/her hump to find a cure/treatment for cancer.
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88(2):277-85, 1997 Jan.24
Boehm T, Folkman J, Browder T, and O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390(6658):404-7, 1997 Nov.27
Mr. Miller
|
